{"id":"W4415519763","doi":"10.1016/j.jtho.2025.09.045","title":"OA05.04 A Randomized Phase 3 Study of Niraparib Plus Pembrolizumab as Maintenance Therapy for Advanced/Metastatic NSCLC: ZEAL-1L","year":2025,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"GlaxoSmithKline (Canada)","funders":"","keywords":"Pembrolizumab; Maintenance therapy; Phases of clinical research; Antibody therapy; Phase (matter)","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001790693,0.001622893,0.002940607,0.000556595,0.0005303717,0.001800419,0.001185432,0.001223508,0.008057143],"category_scores_gemma":[0.001223248,0.0007072099,0.002273413,0.000487322,0.001537629,0.001339842,0.0004845155,0.003780548,0.001576991],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001360983,"about_ca_system_score_gemma":0.001913738,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002109051,"about_ca_topic_score_gemma":0.005143043,"domain_scores_codex":[0.9993606,0.0003060444,0.00003301385,0.0001071729,0.0000486871,0.000144449],"domain_scores_gemma":[0.9992574,0.000155053,0.0001325812,0.00007510954,0.00003749728,0.0003423476],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9581167,0.009579087,0.0008972283,0.0003851379,0.001405914,0.00004058353,0.00005497259,0.0006061558,0.004882717,0.0001997597,0.001446282,0.02238545],"study_design_scores_gemma":[0.926698,0.06897774,0.002029973,0.00001746712,0.0004611659,0.00003153814,0.00002433864,0.000369695,0.0004043041,0.0001285268,0.0008431112,0.00001412958],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9856551,0.003935527,0.0007615167,0.0008753351,0.0006332869,0.002807848,0.001939001,0.0002184609,0.003173902],"genre_scores_gemma":[0.9850367,0.002068834,0.001524271,0.001432148,0.000356399,0.002735277,0.002361971,0.00004771564,0.004436743],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008057143,"threshold_uncertainty_score":0.02695382,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0282952371958041,"score_gpt":0.4549313049148271,"score_spread":0.426636067719023,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}